<DOC>
	<DOCNO>NCT00977223</DOCNO>
	<brief_summary>Data literature previous vitro research conduct investigator ' laboratory ( INSERM U413/EA4310 , University Rouen ) suggest adrenal corticosteroid secretion might control sympathetic nervous system . This neurocrine regulation corticosteroid secretion involve locally release neuropeptides . Among , substance P able stimulate aldosterone cortisol production via NK1 receptor . The aim present study investigate effect NK1 receptor antagonist , aprepitant , adrenocortical secretion healthy volunteer . Aprepitant drug already available treatment nausea induce chemotherapy . In present phase IV trial , plasma aldosterone cortisol level measure treatment aprepitant versus placebo , basal condition activation adrenocortical function various stimulus , include upright posture , metoclopramide , insulin-induced hypoglycaemia . All healthy volunteer give two substance ( aprepitant placebo ) random order two one-week period separate 14 day-wash-out . This study allow determine role substance P control corticosteroid production normal man .</brief_summary>
	<brief_title>Effects Substance P Antagonists Adrenal Secretion</brief_title>
	<detailed_description>STUDY DESIGN Phase IV , proof concept , interventional , monocentric , randomise , double blind , cross-over study : The effect substance P antagonist ( Emend ) corticosteroid secretion compare placebo . STUDY OBJECTIVES Main objective : verify adrenal corticosteroid secretion actually control substance P. Secondary objective : determine physiological condition involve control adrenocortical function tachykinins . NUMBER OF SUBJECTS 20 healthy volunteer ELIGIBILITY CRITERIA ( see ) DURATION OF STUDY Overall duration : 13 month Inclusion period : 12 month Follow period ( 1 subject ) : 5 week Exclusion period : 1 month ENDPOINTS PRIMARY ENDPOINT : blood aldosterone variation orthostatic test SECONDARY ENDPOINTS Basal aldosterone alteration Aldosterone variation metoclopramide &amp; hypoglycaemia test Basal stimulate ( 3 different test ) alteration renin , cortisol &amp; ACTH REGULATORY AUTHORIZATIONS Ethics committee authorization : dec 18th , 2008 Regulatory authorization : march 3rd , 2009</detailed_description>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Substance P</mesh_term>
	<mesh_term>Neurokinin A</mesh_term>
	<criteria>Male subject ; Age range 18 30 year old ; Submitted social security regimen ; Agreeing study &amp; Informed consent form sign ; Body mass index ( [ weight ( kg ) /height ( ) ] Â² ) &lt; 27 ; No treatment receive 6 week inclusion ; No anomaly : complete clinical examination , pulse blood pressure measurement , ECG ; No biological abnormality follow biological testing : Hematology : white &amp; red blood cell &amp; platelet count , haemoglobin , hematocrit Blood biochemistry : sodium , potassium , chloride , bicarbonate , creatinine , urea Urinary biochemistry ( 24 h collection ) : cortisol , aldosterone Serologies : HIV , HBV , HCV No participation clinical trial 3 month inclusion . Subject agree study impossible followup ; Known history significant medical surgical pathology , notably endocrine ; Renal hepatic insufficiency ; Nephrotic syndrome ; Edematous syndrome ; Hypertension postural hypotension ; Cardiac rhythm conduction pathology ; Cardiac insufficiency ; Epilepsy ; Significant psychiatric disorder ; Known history severe allergy , hypersensitivity aprepitant ant/or metoclopramide ; Hereditary problem fructose intolerance , glucosegalactose malabsorption sucraseisomaltase deficit ; Impaired lactose tolerance .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Aldosterone</keyword>
	<keyword>Substance P</keyword>
	<keyword>Cortisol</keyword>
	<keyword>Aprepitant</keyword>
	<keyword>Adrenal gland</keyword>
</DOC>